| Literature DB >> 30234007 |
Filippo Carta1, Cinzia Mariani1, Giovanni B Sambiagio2, Natalia Chuchueva3, Elisa Lecis1, Clara Gerosa4, Roberto Puxeddu1.
Abstract
The present study analyzed the results of the endoscopic approach to T1, T2 and selected T3 supraglottic carcinoma with the aim of reviewing functional and oncologic outcomes after different types of endoscopic supraglottic laryngectomies. This is a retrospective clinical study of 42 consecutive patients (mean age of 61.8 years, 33 males, 9 females) treated by the senior author for supraglottic squamous cell carcinoma with a transoral CO2 laser approach and reviewed from November 2010 to September 2017. Surgical procedures were classified according to the European Laryngological Society. In addition to the standardized transoral supraglottic laryngectomies, we introduced a modified type IVb by sparing the inferior third of the arytenoid if not directly involved in the tumor. Swallowing was evaluated with the Swallowing Performance Status Scale reported by the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology. Survival probabilities were estimated using Kaplan-Meier curves. Two type I, 2 type IIa, 2 type IIb, 3 type IIIa, 12 type IIIb, 13 type IVa, 3 type modified IVb, and 5 type IVb supraglottic laryngectomies were performed. Twenty-one patients (50%) underwent primary neck dissection. The pathologic TNM classification according to the 8th edition of the American Joint Committee on Cancer system was as follows: 9 pT1cN0, 2 pT1N0, 1 pT1N1, 7 pT2cN0, 1 rypT2cN0, 9 pT2N0, 4 pT2N1, 2 ypT2N1, 2 pT3cN0, 2 rypT3cN0, 1 pT3N1, and 2 pT3N2b. Mean follow-up was 3.4 years (range of 9 months to 6 years). According to the Kaplan-Meier analysis, 5-year disease-specific survival, local-relapse-free survival, nodal-relapse-free survival, overall laryngeal preservation and overall survival of patients without previous head and neck radiotherapy/open surgery were 100%, 95.2%, 87.8%, 100%, and 64.6%, respectively. Patients who underwent type I, IIa, and IIb resections (n = 6) started oral feeding the day after surgery, patients who underwent type III-IVb modified resections (n = 31) started oral feeding 3-4 days after surgery, and patients who underwent standard type 4b resections (n = 5) started oral feeding 7 days after surgery. Three months after surgery, patients without a clinical history of previous head and neck radiotherapy/open surgery who underwent type III, IVa, and modified IVb resections showed significantly better swallowing compared to patients who underwent standard type IVb resection: grade 4-6 impairment of swallowing in 8 and 66.7% of cases, respectively (p = 0.006072); patients with a clinical history of previous head and neck radiotherapy/open surgery who underwent type III, IVa, and modified IVb resections showed not statistically significant better swallowing compared to patients who underwent standard type IVb resection: grade 4-6 impairment of swallowing at 3 months in 16.7% and 50% of cases, respectively (p = 0.23568). Transoral CO2 laser supraglottic laryngectomy is an oncologic sound alternative to traditional open neck surgery and chemo-radiotherapy. Recovery of swallowing is significantly worsened after total resection of the arytenoid. Modified type IVb procedure leaving intact, when possible, the inferior third of the arytenoid and consequently the glottic competence, improves functional outcome.Entities:
Keywords: CO2 laser; endoscopic surgery; functional results; microlaryngoscopy; supraglottic carcinoma; swallowing
Year: 2018 PMID: 30234007 PMCID: PMC6131582 DOI: 10.3389/fonc.2018.00321
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Mean hospitalization time, need for temporary tracheostomy, and need for naso-gastric feeding tube for each type of transoral supraglottic laryngectomy/group of patients.
| All patients ( | 9.8 | 9.7/23 | 9.6 |
| Type I ESL ( | 4 | 3/1 | – |
| Type II ESL ( | 6 | 3/1 | – |
| Type III ESL ( | 10 | 9/9 | 7 |
| Type IVa ESL ( | 10 | 10/8 | 9 |
| Type IVb mod ESL ( | 10 | 10/1 | 9 |
| Type IVb ESL ( | 14 | 15/3 | 19 |
| Naive patients ( | 9.6 | 9.6/19 | 7.7 |
| Type I ESL ( | 3 | – | – |
| Type II ESL ( | 6.5 | 3/1 | – |
| Type III ESL ( | 10 | 9/9 | 7 |
| Type IVa ESL ( | 10 | 10/6 | 8.6 |
| Type IVb mod ESL ( | 10.5 | 10/1 | 9 |
| Type IVb ESL ( | 11.3 | 14/2 | 17.5 |
| Patients with previous treatments ( | 10.4 | 10/4 | 10 |
| Type I ESL ( | 5 | 3/1 | – |
| Type II ESL ( | 4.5 | – | – |
| Type III ESL ( | 9 | – | 7 |
| Type IVa ESL ( | 10 | 10/2 | 10 |
| Type IVb mod ESL ( | 9 | – | 9 |
| Type IVb ESL ( | 18 | 17/1 | 22 |
Patients with a clinical history of previous head and neck radiotherapy/open surgery.
Patients who underwent adjuvant radiotherapy.
| 1/M/67 | cT2 N1 | IVa | pT2 N1 | Involved (deep margin) | Yes (No residual tumor) | Yes | 1 ipsilateral lymph node (extracapsular spread) | 66 Gy | No | NED after 1 year of follow-up |
| 2/F/70 | cT2 N0 | IVa | pT2 cN0 | Involved (deep margin) | No | No | No | 66 Gy | 8 cycles of CISPLATIN | NED after 5.3 years of follow-up |
| 3/M/63 | cT1 N1 | IIIb | pT2 N1 | Free | No | No | 1 ipsilateral lymph node | 54 Gy | 12 cycles of CISPLATIN | DOC after 4.2 years of follow-up |
| 4/F/52 | cT2 N2b | IVa | pT3 N2b | Involved (deep margin) | Yes (No residual tumor) | No | Multiple (2) ipsilateral lymph nodes | 66 Gy | No | NED after 5.8 years of follow-up |
| 5/M/63 | cyT2 N2c | IIIb | ypT2 N1 | Free | No | No | 1 ipsilateral lymph node | 54 Gy | No | NED after 5 years of follow-up |
| 6/F/57 | cT2 N0 | IVa | pT3 cN0 | Free | No | No | No | 54 Gy | No | NED after 3.5 years of follow-up |
| 7/M/61 | cT2 N2a | Modified IVb | pT3 N2b | Close (deep margin) | Yes (No residual | No | 1 ipsilateral lymph node (extracapsular spread) | 66 Gy | No | DOC after 1.6 years of |
| 8/M/80 | cT1 N0 | IVa | PT2 N1 | Free | No | No | 1 ipsilateral lymph node | 54 Gy | No | DOC after 0.7 years of follow-up |
Patient with a clinical history of previous head and neck open surgery.
Patient who previously underwent neoadjuvant chemotherapy.
Swallowing results according to the Swallowing Performance Status Scale of all patients without history of previous head and neck radiotherapy/open surgery.
| Grade 1 | 15 | 1 | 3 | 8 | 3 | ||
| Grade 2 | 8 | 4 | 3 (1) | 1 | |||
| Grade 3 | 5 | 1 (1) | 2 | 1 | 1 | ||
| Grade 4 | 2 | 1 | 1 | ||||
| Grade 5 | 1 | 1 | |||||
| Grade 6 | 1 | 1 | |||||
| Grade 7 | |||||||
| Total | 32 (7) | 1 | 3 | 14 (2) | 9 (4) | 2 (1) | 3 |
Number of patients who underwent adjuvant radiotherapy.
Swallowing results according to the Swallowing Performance Status Scale of all patients who previously underwent head and neck radiotherapy/open surgery.
| Grade 1 | 2 | 1 | 1 | ||||
| Grade 2 | 3 | 1 | 2 (1) | ||||
| Grade 3 | 3 | 1 | 1 | 1 | |||
| Grade 4 | 2 | 1 | 1 | ||||
| Grade 5 | |||||||
| Grade 6 | |||||||
| Grade 7 | |||||||
| Total | 10 (1) | 1 | 1 | 1 | 4 (1) | 1 | 2 |
Number of patients who underwent adjuvant radiotherapy.
Recurrences.
| 1/M/57 | No | No | cT2N0 | IIIa | pT2cN0/R0 | No | Ipsilat. Neck/0.4 years | Ipsilat. ND + RT (66 Gy)/rpT0N2a | Primary/2 years | IIb OPHL/rypT2cN0 | DOC/5.1 years |
| 2/M/81 | No | No | cT2N0 | IIIb | pT2cN0/R0 | No | Bilat. Neck/0.7 years | Bilat. ND/rpT0N2b | No | / | DOC/1 year |
| 3/F/48 | No | CHT-RT for cT3 supraglottic SCC | ycT3N0 | IVb | ypT3cN0/R0 | No | Ipsilat. Neck/0.3 years | Ipsilat. ND/rypT0N2b | No | / | NED/5.2 years |
| 4/F/43 | No | CHT-RT for cT3 supraglottic SCC | yCT3N0 | IIIb | pT3cN0/R1 | No | Primary/1.2 years | TL/rypT3cN0 | No | / | NED/5 years |
| 5/F/72 | No | No | cT1N1 | IVa + Ipsilat. ND | pT1N1/R0 | No | Contralat. Neck/1.8 years | Contralat. ND + RT (66 Gy)/rpT0N2a | No | / | NED/5.2 years |
| 6/M/55 | Head and Neck surgery for pT4aN1 oral SCC | RT (54 Gy) | cT2N0 | IVa | ypT2cN0/R0 | CHT | Ipsilat. Neck/1 year | Ipsilat. ND + CHT/rypT0N2a | Ipsilat. Neck/2 years | CHT | DOD/2.3 years |
| 7/M/69 | Head and Neck surgery for pT1N2 oral SCC | RT (54 Gy) | cT3N0 | IVa | ypT3cN0/R0 | No | Primary/0.4 years | TL + CHT/rypT4acN0 | Primary/1.2 years | CHT | DOD/2.5 years |
| 8/M/53 | Head and Neck surgery for pT1N2b laryngeal SCC | CHT-RT (66 Gy) | rycT2N0 | IVb | rypT2cN0/R0 | CHT | Primary/2.7 years | TL/rypT3cN0 | No | / | NED/3.6 years |
| 9/M/66 | Head and Neck surgery for pT2N0 laryngeal SCC | No | rcT1N0 | I | rpT1cN0/R0 | No | Ipsilat. Neck/0.2 years | Ipsilat. ND + RT (66Gy/rypT0N3 | No | / | DOC/1.1 years |
CHT: chemo-radiotherapy; RT: radiotherapy; ND: neck dissection; TL: total laryngectomy; NED: no evidence of disease; DOD: died of disease; DOC: died of other causes.
5-year survival outcomes.
| All series ( | 93.1% SE: 4.7 | 90.5% SE: 6% | 83% SE: 6.3% | 90.7% SE: 5.2% | 64.9% SE: 8.8% |
| T1 ( | 100% | 100% | 80.1% SE: 6% | 100% | 70% SE: 6% |
| T2 ( | 95.7% SE: 4% | 91.3% SE: 5% | 83.6% SE: 7% | 95.7% SE: 4% | 66% SE: 6% |
| T3 ( | 71.4% SE: 14% | 71.4% SE: 14% | 85.7% SE: 13% | 71.4% SE: 14% | 43% SE: 14% |
| Naive patients ( | 100% | 95.2% SE: 4.6% | 87.8% SE: 6.3% | 100% | 64.6% SE:16.3% |
| T1 ( | 100% | 100% | 85.7% SE: 13.2% | 100% | 75% SE: 18.9% |
| T2 ( | 100% | 91.7% SE: 8% | 87.8% SE: 8% | 100% | 65% SE: 12.8% |
| T3 ( | 100% | 100% | 100% | 100% | 66.7% SE: 27.2% |
| Previously treated ( | 77.8% SE: 13.9% | 65.6% SE: 16.4% | 70% SE:14.5% | 65.6% SE: 16.4% | 70% SE: 14.5% |
| T1 (3) | 100% | 100% | 66.7% SE: 27.2% | 100% | 66.7% SE: 27.2% |
| T2 (3) | 66.7% SE: 27.2% | 50% SE: 35.6% | 66.7% SE: 27.2% | 50% SE: 35.4% | 66.7% SE: 27.2% |
| T3 (4) | 75% SE: 21.7% | 50% SE: 25% | 75% SE: 21.7% | 50% SE: 25% | 75% SE: 21% |
SE: standard error.
Comparative results of functional results from different studies.
| Puxeddu et al. ( | 12 | 1 (8.3%) | 0 (0%) | 0 (0%) |
| Cabanillas et al. ( | 26 | 13 (50%) | 2 (7.7%) | 4 (15.4%) |
| Bernal-Sprekelsen et al. ( | 121 | 2 (1.7%) | 2 (1.7%) | |
| Chiesa Estomba et al. ( | 31 | 6 (19.4%) | 2 (6.5%) | 4 (13%) |
| Piazza et al. ( | 96 | 10 (11%) | 0 (0%) | 0 (0%) |
| Bertolin et al. ( | 15 | / | 0 (0%) | 0 (0%) |
Patients included in the study with the analysis of the functional results.